Corporate

You heard it here first.

 
 
 

Our news

Bringing you the latest!

Corporate

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

Corporate - Investors

17 December 2020

First long-acting injectable (LAI) antipsychotic using MedinCell’s technology reaches Phase 3 clinical study primary completion date

Corporate

12 November 2020

 
 

CONTACT

  • This field is for validation purposes and should be left unchanged.